Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Very Low Dose LSD in Healthy Older Volunteers
NCT04421105Phase 1Completed
- Sponsor
- Eleusis
- Start
- Jun 2015
- Primary completion
- Oct 2015
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, randomised, double-blind trial of Lysergide in Alzheimer's disease (AD) (4 arms), sponsored by Eleusis. Primary endpoints: Safety and Tolerability of Very Low Dose LSD at 2.5 weeks and Pharmacokinetics of Very Low Dose LSD at 12 hours. Started Jun 2015; status: completed.
02
Drugs
Lysergide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04421105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04421105.